The global problem of multidrug-resistant bacterial pathogens requires urgent actions, including the development of therapies supplementary or alternative to antibiotics.
One of the infection control options could be phage therapy.
This article gives a brief overview of phage therapy potentials as well as the challenges it faces in order to become a widely accepted form of infection treatment.
The history of antimicrobial drug discovery includes more than 15 classes of antimicrobials that became a cornerstone in microbial infection control and management and saved many lives The widespread antibiotic resistance in a variety of microbiota, including human and animal pathogens, is the consequence of extensive use of antibiotics in human and veterinary medicine and agriculture. What can be done to limit and contain it? It is clear that the massive antimicrobial usage, which inevitably results in selection of the corresponding resistance mechanisms, has to be lessened. Unfortunately, the trends in antibiotic production and consumption are quite opposite, suggesting a very substantial growth for both humans and animals 9, 10 .
All major classes of antimicrobials were discovered during the golden age of antibiotic discovery, which came to an end more than 50 years ago . Sixth, bacteriophages could play a significant role in restricting the evolution and spread of antibiotic resistance 16, 17 . Seventh, phages may be effectively used for diagnostic purposes Pyo-bacteriophage, which is a mix of bacteriophages targeting all these pathogens. Preliminary results of the clinical trial have been published 24, 25 , which hopefully will result in a broader recognition of phage therapy for treatment of multidrug resistant infections.
Once widely accepted, phage can be used as a valuable alternative option to lessen antibiotic usage and corresponding resistance.
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